Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (737)	9/30/1998 1:55:00 PM
From: Rocketman	Respond to of 3202

I think it is still a great investment. All the biotechs are sucking for air. There are basically no major buyers of biotech stocks right now and so all of the valuations are way too low. When they turn around (and they eventually will) I would expect INCY to lead the pack. Rman

To: Harold Engstrom who wrote (737)	10/1/1998 2:18:00 AM
From: Vector1	Read Replies (1) \| Respond to of 3202

Harold, i think INCY is an excellent investment at current levels. The price has gotten crushed because the street believes that there is increasing competition (particularly PNK's JV with Craig Ventor)and as a result INCY's database will be less valuable. In additon the Street is concerned that INCY's new venture to create a detailed map of Single Nucleotide Polymorphisms will cost a lot of money and hurt near term earnings. INCY's is planning on creating a tracking stock for this venture and I believe a substantial portion of the funding for the tracking stock will be made up of Pharma companies in INCY's current syndicate. Tracking stocks have become a big negative for biotech companies thanks to Genzyme. I added to my personal position at $20 and may buy more. V1